DUBLIN, Aug. 06, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/c6nl4c/investigation) has announced the addition of the "Investigation Report on China's Etanercept Market, 2010-2019" report to their offering.
There are over 300 million people suffering from arthritis around the world. According to the statistics of Centers for Disease Control and Prevention (CDC), about 50 million Americans suffer from arthritis and this number will rise to 67 million in 2030 on present trends. Also, direct spending (drugs) and indirect spending (productivity decline) amount to USD 128 billion each year. According to the statistics, there are about 100 million patients with arthritis in China, among of which 5-10 million are patients with rheumatoid arthritis (RA). In China, the disability rate of RA is 50% if left untreated in two years and 70% in three years.
Developed by Pfizer under the trade name of Enbrel, etanercept is the first completely humanized soluble tumor necrosis factor antagonist for the treatment of RA and ankylosing spondylitis. Its sales value has surpassed USD 8 billion for four successive years. Globally, etanercept is the fifth best-selling drug in 2014 with sales value reaching up to USD 8.54 billion.
After entering China in 2010, etanercept develops fast with annual sales value rising from CNY 2.45 million in 2010 to CNY 23.45 million in 2014 and CAGR during this period reaching up to 75.9%. Currently, etanercept in the Chinese market is monopolized by Boehringer Ingelheim (Germany). According to this market survey, the price range of 25 mg (one injection per package) etanercept in the sample hospitals in 2014 was CNY 2032.97-2386.28/package. Although etanercept's market size is not very big due to its relatively high price, it still keeps growing fast. With the economic development and rising incomes, the market for etanercept will be big.
Key Topics Covered:
1.1 Related Concepts of Etanercept
2 Market Profile of Etanercept in China
3 Survey on Sales Status of Etanercept in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Etanercept in China, 2010-2014
5 Survey on Dosage Forms of Etanercept in China, 2010-2014
6 Reference Price of Etanercept in Chinese Hospitals in 2014
7 Major Manufacturers of Etanercept in Chinese Market, 2010-2014
8 Market Outlook of Etanercept in China, 2015-2019
- Boehringer Ingelheim
For more information visit http://www.researchandmarkets.com/research/c6nl4c/investigation
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets